News | March 18, 2009

Partnership for Prevention Advocates Daily Aspirin Use to Prevent Heart Attack, Stroke

March 18, 2009 - The U.S. Preventive Services Task Force (USPSTF) found that regular aspirin use reduces first heart attacks in men and first strokes in women and recommends daily aspirin use for certain patient populations.
The recommendation applies to men between the ages of 45 and 79 and to women 55 to 79. Aspirin should be used when the benefits outweigh the harms for potential gastrointestinal bleeding.
The new recommendation underscores the importance of healthcare providers discussing aspirin use with patients. A 2007 study sponsored by the American College of Preventive Medicine found that the factor most strongly associated with appropriate aspirin use is a conversation about aspirin between a patient and healthcare provider. The recommendation will help clinicians assess individuals' risk for heart disease and stroke, and it gives clinicians guidance about age- and gender-specific benefits and harms of aspirin use.
A separate study by Partnership for Prevention found that if 90 percent of people who could benefit from aspirin actually took the daily dose, an additional 45,000 lives would be saved each year.
The National Committee for Quality Assurance, which measures the quality of care provided by health plans, recently recognized that aspirin use is effective in reducing cardiovascular events. To encourage appropriate aspirin use, NCQA has proposed that health plans measure their members' use of aspirin as well as the extent to which clinicians discuss aspirin use with patients.
Partnership for Prevention has established a Task Force on Appropriate Aspirin Use to encourage appropriate use of aspirin to prevent heart attacks and strokes.
"The updated USPSTF recommendation emphasizes the importance of considering the potential benefits and downsides of using aspirin for cardiovascular prevention. It's clear that discussing aspirin use with patients in the targeted age groups should become standard practice for clinicians," said Michael Pignone, M.D., a member of Partnership's Task Force and chief of general internal medicine at the University of North Carolina.
Partnership for Prevention is a non-partisan, non-profit organization of business, healthcare, and government leaders who are working to make disease prevention and health promotion a higher priority in the nation's health policies and programs
Source: Partnership for Prevention
For more information: www.prevent.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init